StemRIM Inc.
Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
Earlier from Stemrim
- Patent Registration in South Korea for Redasemtide in Cartilage Disorders
- StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
- StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
- StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea